Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

An early look at selective RET inhibitor resistance: new challenges and opportunities

British Journal of Cancer volume 124, pages 1757–1758 (2021)Cite this article

Subjects

Summary

Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, in most cases, due to RET-independent mechanisms.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).

    Article  Google Scholar 

  2. Drilon, A., Hu, Z. I., Lai, G. G. Y. & Tan, D. S. W. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat. Rev. Clin. Oncol 15, 151–167 (2018).

    Article  CAS  Google Scholar 

  3. Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J. et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell Lung cancer. N. Engl. J. Med. 383, 813–824 (2020).

    Article  CAS  Google Scholar 

  4. Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S. et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J. Clin. Oncol. 38, 9515–9515 (2020).

    Article  Google Scholar 

  5. Lin, J. J. & Shaw, A. T. Resisting resistance: targeted therapies in lung cancer. Trends Cancer 2, 350–364 (2016).

    Article  Google Scholar 

  6. Lin, J. J., Liu, S. V., McCoach, C. E., Zhu, V. W., Tan, A. C., Yoda, S. et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann. Oncol. 31, 1725–1733 (2020).

    Article  CAS  Google Scholar 

  7. Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K. et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J. Thorac. Oncol. 15, 541–549 (2020).

    Article  CAS  Google Scholar 

  8. Gainor, J., Curigliano, G., Doebele, R. C., Lin, J. J., Ou, S. H., Miller, S. et al. OA05.02 analysis of resistance mechanisms to pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) from the ARROW study. J. Thorac. Oncol. 16, S5 (2021).

    Article  Google Scholar 

  9. Subbiah, V., Shen, T., Terzyan, S. S., Liu, X., Hu, X., Patel, K. P. et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann. Oncol. 32, 261–268 (2021).

    Article  CAS  Google Scholar 

  10. Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6, 1118–1133 (2016).

    Article  CAS  Google Scholar 

  11. Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y. et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 26, 2654–2663 (2020).

    Article  CAS  Google Scholar 

  12. Rosen, E. Y., Johnson, M. L., Clifford, S. E., Somwar, R., Kherani, J. F., Son, J. et al. Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 27, 34–42 (2021).

    Article  CAS  Google Scholar 

  13. Drilon, A. E., Zhai, D., Rogers, E., Deng, W., Zhang, X., Ung, J. et al. The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models. J. Clin. Oncol. 38, 3616–3616 (2020).

    Article  Google Scholar 

  14. Zhu, V. W., Madison, R., Schrock, A. B. & Ou, S. I. Emergence of high level of MET amplification as off-target resistance to selpercatinib treatment in KIF5B-RET NSCLC. J Thorac. Oncol. 15, e124–e127 (2020).

    Article  CAS  Google Scholar 

  15. Sequist, L. V., Han, J. Y., Ahn, M. J., Cho, B. C., Yu, H., Kim, S. W. et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 21, 373–386 (2020).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author information

Authors and Affiliations

  1. Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Jessica J. Lin & Justin F. Gainor

Authors
  1. Jessica J. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justin F. Gainor
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.J.L. and J.F.G. contributed to the writing and review of this manuscript.

Corresponding author

Correspondence to Justin F. Gainor.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Data availability

Not applicable.

Competing interests

J.J.L. has served as a compensated consultant for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, and Turning Point Therapeutics; received honorarium and travel support from Pfizer; received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, and Novartis; received CME funding from OncLive, MedStar Health, and Northwell Health. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, AstraZeneca, Pfizer, Incyte, Novartis, Merck, Mirati, EMD Serono, Glyde Bio, ImageAb, Agios, Amgen, and Array; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee of Ironwood Pharmaceuticals.

Funding information

Not applicable

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, J.J., Gainor, J.F. An early look at selective RET inhibitor resistance: new challenges and opportunities. Br J Cancer 124, 1757–1758 (2021). https://doi.org/10.1038/s41416-021-01344-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-021-01344-7

This article is cited by

Search

Advanced search

Quick links